Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin to Attenuate Progressive Respiratory Decline in IPF (MAVRIC)
NCT07520110Phase 3Not yet recruiting
- Sponsor
- University of Massachusetts
- Start
- Sep 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liquid metformin (Aspargo Labs) in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by University of Massachusetts. Primary endpoint: Time to death, non-elective hospitalization, or lung transplantation at 24 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07520110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07520110.